Results 121 to 130 of about 1,503 (160)
Some of the next articles are maybe not open access.
Plasma oxypurinol as a measure of adherence in clinical trials
Annals of the Rheumatic Diseases, 2018Adherence to urate-lowering therapy (ULT) in people with gout is often poor. A recent systematic review revealed 10%–46% of people with gout adhere to treatment.1 Among chronic diseases, gout has particularly low adherence rates.2 Adherence in clinical trials of ULT is a particularly important issue, as the primary efficacy endpoint for most studies ...
Lisa K, Stamp +6 more
openaire +2 more sources
Allergic Reaction to Allopurinol with Cross-Reactivity to Oxypurinol
Annals of Internal Medicine, 1976A 25-year-old white man with gout and nephropathy and with a previous reaction to allopurinol was given a trial dose of oxypurinol. He developed malaise, a generalized erythematous reaction with edema, pruritus, and emesis; this was clinically identical to the reaction he experienced with allopurinol.
O, Lockard +3 more
openaire +2 more sources
The Effect of Dietary Protein on the Clearance of Allopurinol and Oxypurinol
New England Journal of Medicine, 1985A decrease in dietary protein is known to depress renal plasma flow and creatinine clearance. Using a randomized crossover design, we investigated the pharmacokinetics of allopurinol and its principal metabolite, oxypurinol, after oral administration of 600 mg of allopurinol in six normal subjects receiving a high-protein (268 g per day) or low-protein
W G, Berlinger, G D, Park, R, Spector
openaire +2 more sources
Free Radical Research Communications, 1988
Allopurinol has been employed as a "specific" inhibitor of xanthine oxidase in studies of hypoxic/reoxygenation injury. Pulse radiolysis was used to establish rate constants for the reactions of allopurinol and its major metabolite oxypurinol with hydroxyl radicals: values were (1.45 +/- 0.24) x 10(9) M-1 s-1 for allopurinol and (4.95 +/- 0.84) x 10(9)
Barry Halliwell, B M Hoey
exaly +3 more sources
Allopurinol has been employed as a "specific" inhibitor of xanthine oxidase in studies of hypoxic/reoxygenation injury. Pulse radiolysis was used to establish rate constants for the reactions of allopurinol and its major metabolite oxypurinol with hydroxyl radicals: values were (1.45 +/- 0.24) x 10(9) M-1 s-1 for allopurinol and (4.95 +/- 0.84) x 10(9)
Barry Halliwell, B M Hoey
exaly +3 more sources
Oxypurinol reduces focal ischemic brain injury in the rat
Neuroscience Letters, 1991When measured within 2 days of a unilateral occlusion of the middle cerebral artery (MCA) combined with tandem occlusion of the ipsilateral common carotid artery in rats, contralateral neurological deficits were detectable, with brain swelling and a consistent degree of neocortical infarction in the ipsilateral hemisphere.
Y, Lin, J W, Phillis
openaire +2 more sources
Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation [PDF]
Experimental Cell Research, 2016 Allopurinol and its active metabolite, oxypurinol are widely used in the treatment of gout and hyperuricemia. They inhibit xanthine oxidase (XO) an enzyme in the purine degradation pathway that converts xanthine to uric acid. This investigation examined the effect of allopurinol and oxypurinol on bone formation, cell number and viability, gene ...
Jacob George +2 more
exaly +5 more sources
Effect of furosemide on renal excretion of oxypurinol and purine bases
Metabolism, 2001To examine whether furosemide affects the plasma concentration and urinary excretion of purine bases and oxypurinol, we administered allopurinol (300 mg) orally to 6 healthy subjects and then administered furosemide (20 mg) intravenously 10 hours later. Furosemide (20 mg) decreased the urinary excretion of uric acid by 40% (P < .01), oxypurinol by 39% (
T, Yamamoto +4 more
openaire +2 more sources
Urinary-Tract Stones Resulting from the Excretion of Oxypurinol
New England Journal of Medicine, 1975COMPOUNDS that inhibit the enzyme, xanthine oxidase, are useful in the treatment of disorders of purine metabolism.
A R, Landgrebe, W L, Nyhan, M, Coleman
openaire +2 more sources
The pharmacokinetics of oral and intravenous allopurinol and intravenous oxypurinol in the horse
Journal of Veterinary Pharmacology and Therapeutics, 1995The pharmacokinetics of oral and intravenous allopurinol was studied in five horses and compared with intravenous oxypurinol. The plasma concentration vs. time curves, following intravenous administration of 5 mg/kg, were best described by the biexponential equations Cp = 106.58e‐25.141+ 159.93e‐10.96tfor allopurinol and Cp = 321.09e‐972t+ 82.39e‐0 ...
P C, Mills, M, Dunnett, N C, Smith
openaire +2 more sources
Effect of Amino Acids on the Excretions of Purine Bases and Oxypurinol
Nephron, 2008To investigate whether or not amino acids affect the urinary excretion of purine bases and oxypurinol, a 12% amino acid solution was infused to 6 subjects who took allopurinol (300 mg) 6 h before the study. Amino acid infusion increased the urinary excretion and the fractional clearance of uric acid and oxypurinol and decreased the plasma concentration
T, Yamamoto +4 more
openaire +2 more sources